

Covid-19 Maternity In-patient Checklist

	General guidance																																												
Anticoagulation	<p>Whilst an inpatient in St Mary's, all patients need LMWH regardless of severity of illness, unless expected to deliver in next 12 hours.</p> <p>Antenatal</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="2" style="text-align: center;">Antenatal with BMI less than 35</th> </tr> <tr> <th style="text-align: left;">Booking weight</th> <th style="text-align: left;">Dalteparin dose sc once daily</th> </tr> </thead> <tbody> <tr> <td>Less than 50 kg</td> <td>2500 iu</td> </tr> <tr> <td>50-90 kg</td> <td>5000 iu</td> </tr> <tr> <td>More than 90 kg</td> <td>7500 iu</td> </tr> <tr> <td colspan="2" style="text-align: center;">no factor Xa monitoring needed if eGFR >30</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="2" style="text-align: center;">Antenatal with BMI greater than 35</th> </tr> <tr> <th style="text-align: left;">Booking BMI</th> <th style="text-align: left;">Tinzaparin dose sc once daily</th> </tr> </thead> <tbody> <tr> <td>35-40</td> <td>8000 iu</td> </tr> <tr> <td>41-50</td> <td>10,000 iu</td> </tr> <tr> <td>>50</td> <td>12,000 iu</td> </tr> <tr> <td colspan="2">Anti Xa monitoring required 2-4 hours post dose. Commence monitoring after 3rd dose and continue every 3 days until level 0.2-0.4</td> </tr> </tbody> </table> <p>Once discharged home continue for a minimum of 10 days. Discuss with MDT whether to consider continuing prophylaxis for the duration of the remaining pregnancy and for 6/52 postnatal. If antenatal COVID infection after 28/40, score additional 1 point on postnatal VTE risk score.</p> <p>Postnatal</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="2" style="text-align: center;">Postnatal Symptomatic</th> </tr> <tr> <th style="text-align: left;">Patient current weight</th> <th style="text-align: left;">Dalteparin dose sc once daily</th> </tr> </thead> <tbody> <tr> <td>Less than 50 kg</td> <td>2500 iu</td> </tr> <tr> <td>50-90 kg</td> <td>5000 iu</td> </tr> <tr> <td>90-130 kg</td> <td>7500 iu</td> </tr> <tr> <td>131-170 kg</td> <td>10,000 iu</td> </tr> <tr> <td>>170 kg</td> <td>75iu/kg/day</td> </tr> <tr> <td colspan="2">If on antenatal Tinzaparin, continue with this at same dose</td> </tr> <tr> <td colspan="2" style="text-align: center;">Continue dose for longest period; 6 weeks postnatal or 10 days following discharge from hospital</td> </tr> <tr> <td colspan="2" style="text-align: center;">Anti Xa monitoring as per haematology advise</td> </tr> </tbody> </table> <p>If postnatal but asymptomatic with less than 3 VTE risk factor (eg. Covid positive incidental finding on screening for elective section) then give postnatal thromboprophylaxis for duration of inpatient stay and for 10 days following discharge. If postnatal asymptomatic with more than 3 VTE risk factors give VTE prophylaxis as for postnatal symptomatic (see table above)</p>	Antenatal with BMI less than 35		Booking weight	Dalteparin dose sc once daily	Less than 50 kg	2500 iu	50-90 kg	5000 iu	More than 90 kg	7500 iu	no factor Xa monitoring needed if eGFR >30		Antenatal with BMI greater than 35		Booking BMI	Tinzaparin dose sc once daily	35-40	8000 iu	41-50	10,000 iu	>50	12,000 iu	Anti Xa monitoring required 2-4 hours post dose. Commence monitoring after 3 rd dose and continue every 3 days until level 0.2-0.4		Postnatal Symptomatic		Patient current weight	Dalteparin dose sc once daily	Less than 50 kg	2500 iu	50-90 kg	5000 iu	90-130 kg	7500 iu	131-170 kg	10,000 iu	>170 kg	75iu/kg/day	If on antenatal Tinzaparin, continue with this at same dose		Continue dose for longest period; 6 weeks postnatal or 10 days following discharge from hospital		Anti Xa monitoring as per haematology advise	
Antenatal with BMI less than 35																																													
Booking weight	Dalteparin dose sc once daily																																												
Less than 50 kg	2500 iu																																												
50-90 kg	5000 iu																																												
More than 90 kg	7500 iu																																												
no factor Xa monitoring needed if eGFR >30																																													
Antenatal with BMI greater than 35																																													
Booking BMI	Tinzaparin dose sc once daily																																												
35-40	8000 iu																																												
41-50	10,000 iu																																												
>50	12,000 iu																																												
Anti Xa monitoring required 2-4 hours post dose. Commence monitoring after 3 rd dose and continue every 3 days until level 0.2-0.4																																													
Postnatal Symptomatic																																													
Patient current weight	Dalteparin dose sc once daily																																												
Less than 50 kg	2500 iu																																												
50-90 kg	5000 iu																																												
90-130 kg	7500 iu																																												
131-170 kg	10,000 iu																																												
>170 kg	75iu/kg/day																																												
If on antenatal Tinzaparin, continue with this at same dose																																													
Continue dose for longest period; 6 weeks postnatal or 10 days following discharge from hospital																																													
Anti Xa monitoring as per haematology advise																																													

	<p>If an inpatient on ICU, discussion to be had with the Obstetric and ICU MDT as to the LMWH dosing regimen for the patient.</p> <p>VTE suspected</p> <p>If VTE is suspected, for therapeutic anticoagulation - Tinzaparin 175iu/kg once daily (rounded to nearest 1000iu). If total dose >20,000iu discuss with Haematology. Will need Factor Xa level monitoring. Perform after 3rd dose. Once stable monitor twice weekly.</p> <p>Stop thromboprophylaxis, if platelets<50 and use compression stockings (flowtrons not able to be used in COVID patients owing to infection control)</p>
Oxygen	<p>Maintain Sats ≥94% - clearly document amount of O₂ patient requiring ie. litres via nasal specs or O₂%</p> <p>Advise self-proning as much as is possible in the third trimester</p>
Antibiotics	<p>Treat if suspicion of secondary bacterial infection</p> <p>See Microguide antibiotic decision pathway and Microguide > Body systems > Respiratory > Treatment of community acquired pneumonia with COVID.</p> <ul style="list-style-type: none"> - Ceftriaxone 2g IV od or PO Clarithromycin 500mg bd <p>Consider stopping if PCT normal or falling by ≥50%</p>
Steroids	<p>If women have oxygen requirement - Prednisolone 40mg OD orally for 10 days or until discharge whichever is sooner.</p> <p>(if IV needed, 80mg hydrocortisone bd)</p> <p>REMEMBER blood glucose monitoring (x4 per day) – women with diabetes or gestational diabetes likely to require sliding scale insulin.</p>
Antivirals	<p>Avoid Remdesevir in pregnant women</p> <p>If oxygen requirements increase, liaise with Covid MDT re alternatives</p>
Fluids	<p>Initial fluid resuscitation and if clinically indicated thereafter.</p> <p>Aim for neutral balance with 250-500ml bolus then review</p>
Microbiology / virology Ix to be ordered	<p>See Microguide antibiotic decision pathway:</p> <p>COVID swab</p> <p>Sputum culture</p> <p>Urine for legionella/pneumococcal antigen</p> <p>Additional septic screen as indicated (blood, sputum, urine cultures, wound, HVS)</p> <p>Further investigations as guided by Micro/Virology</p>
Blood Ix to be ordered	<p>FBC, U+E, LFT, coag, fibrinogen, procalcitonin, CRP, LDH, ferritin, glucose</p> <p>NT-Pro BNP, Trop T – if concerns regarding cardiac complications</p> <p>Lipase – if abdominal pain</p>
Arterial blood gas frequency	<p>As indicated by clinical condition.</p> <p>Indicated if Sats <94% on FiO₂ >0.4, RR>30bpm despite oxygen</p>
Other Investigations	<p>CXR on admission</p> <p>EKG</p> <p>CTPA – if concerns regarding PE – ideally should be discussed in COVID MDT</p> <p>Echo if concern of cardiac complications</p>
Daily review	<p>Obstetric MDT</p> <p>Medicine – Consultant/Med Reg Bleep ****</p> <p>Early involvement of critical care so they are aware – add to COVID escalation list on Chameleon</p>
Escalation if deterioration	<p>For urgent medical review: Medical Reg Bleep ****</p> <p>For critical care escalation contact via Vocera ask for “Critical care middle grade on</p>

	<p><i>call</i> and/or bleep ****</p> <p>For discussions with COVID MDT Respiratory in-reach referral on ICE and ANP carries Bleep ****</p> <p>Detail specific triggers for escalation</p>
CTG monitoring	Usually once daily unless deterioration in clinical condition / obstetric indication
Fetal ultrasound	Only if clinically indicated and would change management whilst IP. Arrange post COVID scan 3 weeks following infection.
Research / Recovery trial	<p>Offer women the opportunity to enter the recovery trial</p> <p>Contact the 5th floor Research team on ****</p>
UKOSS data collection / local data collection	<p>Submit data to UKOSS: Any woman admitted to hospital with presumed or confirmed COVID-19 infection in pregnancy between 1st March 2020 – 31st March 2021</p> <p>https://www.npeu.ox.ac.uk/assets/downloads/ukoss/forms/UKOSS_COVID-19_v3 - 4-Jan-2021_active_FINAL.pdf</p> <p>Ensure all Covid positive women's hospital numbers are recorded in the consultant anaesthetic office</p>